|
Sun, 05/30/2021 - 05:43 |
Cannabis offers immediate relief from symptoms of nausea, but product use matters |
University of N... |
|
Tue, 08/18/2020 - 03:04 |
An amino acid alleviates hangover symptoms |
HelsinkiUniv |
|
Mon, 05/18/2020 - 02:40 |
ENHERTU Granted Breakthrough Therapy Designation in the U.S. for HER2 Mutant Metastatic Non-Small Cell Lung Cancer |
Daiichi Sankyo |
|
Mon, 05/11/2020 - 03:28 |
ENHERTU Granted Breakthrough Therapy Designation in the U.S. for HER2 Positive Metastatic Gastric Cancer |
Daiichi Sankyo |
|
Wed, 03/25/2020 - 07:55 |
ENHERTU Approved in Japan for Treatment of Patients with HER2 Positive Unresectable or Metastatic Breast Cancer |
Daiichi Sankyo |
|
Thu, 02/20/2020 - 04:52 |
Researchers recommend tapering off of antidepressants rather than abruptly stopping |
AOA |
|
Wed, 01/08/2020 - 21:11 |
Blueprint Medicines Announces FDA Approval of AYVAKIT (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor |
Blueprint Medicines |
|
Wed, 12/11/2019 - 03:27 |
Genentechs Fixed-dose Subcutaneous Combination of Perjeta and Herceptin Comparable to Intravenous Formulations in People With HER2-Positive Breast Cancer |
Genentech |
|
Mon, 12/09/2019 - 18:50 |
DEP cabazitaxel progresses to phase 2 on positive results |
Starpharma |
|
Fri, 11/15/2019 - 17:23 |
New Novartis medicine Adakveo (crizanlizumab) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease |
Novartis |
|
Thu, 08/15/2019 - 18:45 |
FDA Approves Genentechs Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors |
Genentech |
|
Fri, 08/09/2019 - 16:10 |
Janssen Announces U.S. FDA Accelerated Approval for SIRTURO (bedaquiline) as Part of Combination Therapy to Treat Adolescents with Pulmonary Multidrug-Resistant Tuberculosis |
Johnson and Johnson |
|
Thu, 06/27/2019 - 13:18 |
Combination regimen reduced the risk of disease progression or death by 44 percent in newly diagnosed patients who are transplant ineligible |
Johnson and Johnson |
|
Tue, 03/05/2019 - 08:40 |
SPRAVATO uses the first new mechanism of action in decades to treat major depressive disorder 1,2,3 |
Johnson and Johnson |
|
Thu, 02/28/2019 - 09:42 |
FDA Approves Herceptin Hylecta for Subcutaneous Injection in Certain HER2-Positive Breast Cancers |
Genentech |
|
Wed, 02/27/2019 - 00:53 |
FDA expands indication for Soliqua 100/33 |
Sanofi |
|
Mon, 01/07/2019 - 07:04 |
AcelRx Pharmaceuticals announces publication analyzing pooled data on sufentanil sublingual tablets for short-term treatment of moderate-to-severe acute pain |
AcelRx Pharmace... |
|
Fri, 12/21/2018 - 18:00 |
FDA approves first treatment for rare blood disease |
FDA |
|
Fri, 12/21/2018 - 16:11 |
Acorda Therapeutics Announces FDA Approval of INBRIJA (levodopa inhalation powder) |
Acorda |
|
Fri, 12/21/2018 - 04:11 |
Novartis receives European Commission (EC) approval for expanded indication for Kisqali (ribociclib) |
Novartis |
|
Thu, 12/20/2018 - 14:24 |
Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer |
Pfizer |
|
Thu, 12/20/2018 - 13:22 |
Daiichi Sankyo Initiates First Novel-Novel Combination Study of Two Investigational Agents within its AML Franchise in Patients with AML |
Daiichi Sankyo |
|
Thu, 12/20/2018 - 03:42 |
LYNPARZA (olaparib) Meets Primary Endpoint in Phase 3 SOLO-3 Trial for the Treatment of Relapsed BRCA-Mutated Advanced Ovarian Cancer |
Cubist Pharmace... |
|
Wed, 12/19/2018 - 04:35 |
LYNPARZA (olaparib) Approved by FDA for First-Line Maintenance Therapy in BRCA-Mutated Advanced Ovarian Cancer |
Cubist Pharmace... |
|
Mon, 12/17/2018 - 12:54 |
Teva Announces Positive Topline Phase IIIb Results with Fremanezumab in Adults with Migraine Who Did Not Respond to Multiple Classes of Preventive Treatments |
Teva Pharmaceutical |
